|
|
Article: ESTORRA(TM) Phase III Elderly Data Presented at Eleventh International Congress of International Psychogeriatric Association.
- Article from:
- PR Newswire
- Article date:
- August 22, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Sepracor Inc. today announced the presentation of ESTORRA(TM) brand eszopiclone data from a study performed in elderly patients with chronic insomnia. Data from a Phase III, 231-patient, multi-center, randomized, double-blind, placebo-controlled, parallel-group study were presented at the Eleventh International Congress of the International Psychogeriatric Association in Chicago.
In this study, older patients were randomized to receive nightly treatment with eszopiclone 2 mg or placebo, for two weeks. Sleep efficacy endpoints in this study included sleep maintenance, as measured by wake time after sleep onset (WASO), sleep onset, total sleep time (TST) and ...